10 Stocks Losing Big

5. Marker Therapeutics, Inc. (NASDAQ:MRKR)

Marker Therapeutics dropped for a second day on Tuesday, slashing 20.63 percent to close at $1 as investors sold off amid the lack of fresh catalysts to sustain buying appetite.

On Monday, Marker Therapeutics, Inc. (NASDAQ:MRKR) earned a boost from promising results from the first phase study of its experimental treatment for lymphoma patients.

Called the Apollo study, Marker Therapeutics, Inc. (NASDAQ:MRKR) said that its multi-antigen recognizing T cell therapy registered an objective response rate of 66 percent in patients with Non-Hodgkin Lymphoma (NHL), with 50 percent achieving complete responses.

A total of 24 patients were enrolled in the clinical study, with 15 patients having NHL, while the other 9 had HL.

“We are very excited and encouraged by the progress of the study,” said Marker Therapeutics, Inc. (NASDAQ:MRKR) President and CEO Juan Vera.

“We believe that MT-601 could address this critical unmet need and offer new hope to patients who have exhausted multiple lines of treatment, including CAR-T cell therapy,” he noted.